MECP2 and primary effusion lymphoma: Subsequently, interrogation of publically available data sets (Basso et al, 2005) for 5 of these 6 genes (probes were unavailable for LYAR) confirmed low or absent expression in normal B-cell subsets and high expression in either indolent (NUMA1, MECP2, STMN2) or aggressive lymphoid malignancies (H2AFY, CYCLON), including BL, DLBCL and primary effusion lymphoma (PEL), respectively (Fig 1C).